These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29268267)

  • 1. Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia.
    Pastore MR; Capuano V; Bruyère E; Miere A; Corbelli E; Querques L; Tognetto D; Bandello F; Querques G; Souied EH
    Ophthalmologica; 2018; 239(2-3):133-142. PubMed ID: 29268267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Wu TT; Kung YH
    Retina; 2017 Nov; 37(11):2056-2061. PubMed ID: 28590318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
    Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
    Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of the intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to pathologic myopia.
    Wasiluk E; Wojnar M; Obuchowska I; Mariak Z
    Int Ophthalmol; 2020 Apr; 40(4):833-839. PubMed ID: 31788714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optical coherence tomography angiography in myopic choroidal neovascularization after intravitreal ranibizumab.
    Cennamo G; Amoroso F; Schiemer S; Velotti N; Alfieri M; de Crecchio G
    Eur J Ophthalmol; 2019 Mar; 29(2):239-243. PubMed ID: 29991290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
    Cohen SY; Nghiem-Buffet S; Grenet T; Dubois L; Ayrault S; Fajnkuchen F; Delahaye-Mazza C; Quentel G; Tadayoni R
    Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab.
    Ladaique M; Dirani A; Ambresin A
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):542-7. PubMed ID: 25902117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microvasculature Changes of Myopic Choroidal Neovascularization and the Predictive Value of Feeder Vessel Disappearance after Ranibizumab Treatment Revealed Using Optical Coherence Tomography Angiography.
    Giorno P; Iacono P; Scarinci F; Di Renzo A; Varano M; Parravano M
    Ophthalmologica; 2020; 243(4):263-270. PubMed ID: 31838464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.
    Gabrielle PH; Nguyen V; Creuzot-Garcher C; Miguel L; Alforja S; Sararols L; Casaroli-Marano RP; Zarranz-Ventura J; Gillies M; Arnold J; Barthelmes D
    Acta Ophthalmol; 2022 Feb; 100(1):e288-e296. PubMed ID: 33960115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
    Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
    Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY.
    Tan NW; Ohno-Matsui K; Koh HJ; Nagai Y; Pedros M; Freitas RL; Macfadden W; Lai TY
    Retina; 2018 Nov; 38(11):2228-2238. PubMed ID: 28961671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome Predictors of SD-OCT-Driven Intravitreal Ranibizumab in Choroidal Neovascularization due to Myopia.
    Guichard MM; Peters G; Tuerksever C; Pruente C; Hatz K
    Ophthalmologica; 2020; 243(2):154-162. PubMed ID: 31387095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FIVE-YEAR OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA.
    Onishi Y; Yokoi T; Kasahara K; Yoshida T; Nagaoka N; Shinohara K; Kaneko Y; Suga M; Uramoto K; Ohno-Tanaka A; Ohno-Matsui K
    Retina; 2019 Jul; 39(7):1289-1298. PubMed ID: 29746414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.
    Ruiz-Moreno JM; Arias L; Montero JA; Carneiro A; Silva R
    Br J Ophthalmol; 2013 Nov; 97(11):1447-50. PubMed ID: 24026146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study.
    Li S; Ding X; Sun L; Zhao X; Zhang A; Lyu C; Liu B; Zhang J; Jin C; Lu L
    Clin Exp Ophthalmol; 2019 Mar; 47(2):250-258. PubMed ID: 30345611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.
    Wolf S; Balciuniene VJ; Laganovska G; Menchini U; Ohno-Matsui K; Sharma T; Wong TY; Silva R; Pilz S; Gekkieva M;
    Ophthalmology; 2014 Mar; 121(3):682-92.e2. PubMed ID: 24326106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Patterns for Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry.
    Willis J; Morse L; Vitale S; Parke DW; Rich WL; Lum F; Cantrell RA
    Ophthalmology; 2017 Jul; 124(7):935-943. PubMed ID: 28372860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia.
    Rinaldi M; Semeraro F; Chiosi F; Russo A; Romano MR; Savastano MC; dell'Omo R; Costagliola C
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):529-539. PubMed ID: 27680013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
    Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.